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Retention in pre-antiretroviral treatment care in a district  
of Karnataka, India: how well are we doing?
D. Shankar,1 A. M. V. Kumar,2 B. Rewari,3 S. Kumar,3,4 S. Shastri,5 S. Satyanarayana,2  
R. Ananthakrishnan,6 S. B. Nagaraja,7 M. Devi,1 N. Bhargava,1 M. Das,8 R. Zachariah8
‘Pre-antiretroviral treatment (pre-ART) care’ in the Indian context refers to all services pro-
vided to individuals with human immunodeficiency 
virus (HIV) infection between registering at an ART 
centre and receiving the first dose of ART medica-
tion.1 Pre-ART ‘retention’ is an important programme 
indicator, and is defined as the capacity of the health 
system to maintain patients on active follow-up be-
fore ART initiation. Maintaining HIV-infected persons 
in pre-ART care is important to provide effective man-
agement of opportunistic infections, to ensure ART 
initiation at the optimal time, and to promote pre-
vention of HIV transmission in the community.2,3 De-
lays in ART initiation result in increased morbidity 
and mortality, which impact negatively on pro-
gramme performance.
India is currently facing a concentrated HIV epi-
demic, with an estimated 1.7–2.5 million people liv-
ing with HIV.4 Of these, over 65% are considered eligi-
ble for ART,5 implying that about 35% should be 
retained in pre-ART care.6 Such individuals are re-
quired to be registered and maintained on follow-up 
care at ART centres countrywide. A systematic review 
by Rosen et al. showed that only a third of patients 
testing HIV-positive in sub-Saharan Africa are retained 
in care.7 India, like other ART programmes around the 
world, confines routine programme reporting to 
‘on-treatment analysis’, which means that what hap-
pens before ART initiation is unknown. A previous 
study from Karnataka State, India, by Shastri et al. re-
ported a 29% loss to follow-up between HIV testing, 
registration at ART centres and ART initiation among 
eligible individuals.8 However, retention among indi-
viduals who were not yet eligible for ART (pre-ART) 
was not assessed. Knowing the level of retention 
among pre-ART clients could have important pro-
grammatic and public health implications.
In a cohort of HIV-infected persons who were regis-
tered in pre-ART care at an ART centre in the Tumkur 
district of Karnataka State, India, we aimed to 1) re-
port on the proportion lost to follow-up within 1 year 
of registration and 2) determine socio-demographic 
and immunological variables associated with loss to 
follow-up.
METHODS
Study design
This was a retrospective cohort study using routine 
programme data.
Study site, setting and population
The study was conducted at the ART Centre, located 
in the Tumkur District Hospital of Karnataka State, In-
dia. Karnataka is one of the four largest states in South 
India, with a relatively high HIV prevalence of 0.52%.4 
Tumkur, with a population of 2.7 million, is one of 
the high HIV prevalence districts. Karnataka State has 
a total of 55 ART centres, with two located in the 
Tumkur district. All ART centres cater for patients in 
the pre-ART stage as well as those on ART.
The study was conducted between March and No-
vember 2013 and included a cohort of HIV-infected 
persons (aged 15 years) registered in pre-ART care 
from January 2010 to June 2012.
Registration, eligibility for ART and management 
of patients at the ART centre
All HIV-infected persons presenting at ART centres are 
registered in a pre-ART register, and are given a unique 
pre-ART registration number and a treatment card. 
They are then assessed for ART eligibility according to 
national guidelines (Figure 1).6 Those found eligible 
are initiated on ART, while those not eligible (individ-
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Setting: Antiretroviral treatment (ART) Centre in Tumkur 
district of Karnataka State, India. There is no published 
information about pre-ART loss to follow-up from India.
Objective: To assess the proportion lost to follow-up (de-
fined as not visiting the ART Centre within 1 year of regis-
tration) and associated socio-demographic and immuno-
logical variables.
Design: Retrospective cohort study involving a review of 
medical records of adult HIV-infected persons (aged 15 
years) registered in pre-ART care during January 2010–
June 2012.
Results: Of 3238 patients registered, 2519 (78%) were 
eligible for ART, while 719 (22%) were not. Four of the 
latter were transferred out; the remaining 715 individuals 
were enrolled in pre-ART care, of whom 290 (41%) were 
lost to follow-up. Factors associated with loss to follow-up 
on multivariate analysis included age group 45 years, 
low educational level, not being married, World Health 
Organization Stage III or IV and rural residence.
Conclusion: About four in 10 individuals in pre-ART care 
were lost to follow-up within 1 year of registration. This 
needs urgent attention. Routine cohort analysis in the na-
tional programme should include those in pre-ART care 
to enable improved review, monitoring and supervision. 
Further qualitative research to ascertain reasons for loss to 
follow-up is required to design future interventions.
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uals with a CD4 count 350 cells/mm3 or in World 
Health Organization [WHO] Clinical Stage I and II) are 
registered and followed up in pre-ART care. Clients in 
pre-ART care undergo 6-monthly clinical and immu-
nological assessments, including CD4 counts. A deci-
sion to start ART or to continue in pre-ART is made ac-
cordingly. Individuals who are found not to be eligible 
for ART are given a follow-up visit date. Those with a 
borderline CD4 count are monitored at more frequent 
intervals (those with CD4 counts of 350–400 and 400–
500 cells/mm3 are monitored monthly and quarterly, 
respectively).6 In the event of intercurrent illness, indi-
viduals are advised to visit any of the nearest health 
facilities or the ART centre.
If a person registered under pre-ART care does not 
visit the ART centre as scheduled, he/she is listed as a 
‘pre-ART patient with CD4 due’. Measures to trace the 
patient are initiated, and lists of these patients are 
shared with the community care centres (CCCs), com-
munity-based organisations (CBOs), non-governmen-
tal organisations (NGOs), integrated counselling and 
testing centres (ICTCs) and the district AIDS (acquired 
immune-deficiency syndrome) prevention and control 
unit (DAPCU) during routine monthly review meet-
ings. If the patient does not attend for follow-up for a 
further 6 months (meaning that there has not been a 
single visit within a year of registration), this person is 
termed as ‘pre-ART lost to follow-up’.
If a patient declared lost to follow-up from pre-ART 
turns up anytime afterwards, he/she is counselled, 
continued with the previous pre-ART registration 
number and recorded as ‘re-entered (return after loss 
to follow-up)’.
Data and statistical analysis
Data related to the study objectives were sourced from 
National AIDS Control Programme (NACP) treatment 
cards maintained at the ART centre and cross-verified 
against the pre-ART register. Data were double entered 
in a structured data entry format prepared in EpiData 
entry software (Version 3.1, EpiData Association, 
Odense, Denmark) by two independent investigators, 
and validated. Data were summarised as means or me-
dians (for continuous variables) and proportions (for 
categorical variables). The χ² test was used to compare 
proportions. The primary outcome of interest was loss 
to follow-up, and the exposures assessed for associa-
tion were age, sex, education, occupation, marital sta-
tus, WHO clinical staging and CD4 count. The magni-
tude of associations was assessed using relative risks 
and adjusted using a multivariate log-binomial regres-
sion model to control for confounding;9 95% confi-
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FIGURE 1 Management of HIV-infected persons in ART centres according to Indian 
ART operational guidelines, 2012. HIV = human immunodeficiency virus; ART = an-
tiretroviral treatment; WHO = World Health Organization; LFU = lost to follow-up.
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dence intervals were used and a P value  0.05 was considered 
statistically significant. EpiData analysis (version 2.2.2.182) and 
Stata version 12.1 (Stata Corporation, College Station, TX, USA) 
were used for analysis.
Ethics approval
Ethics approval was obtained from the Ethics Committee of the 
National AIDS Control Organisation (NACO), New Delhi, India, 
and the Ethics Advisory Group of the International Union Against 
Tuberculosis and Lung Disease, Paris, France. As the study did not 
involve direct patient interaction, the need for informed consent 
was waived by the ethics committees.
RESULTS
Of 3238 patients registered, 2519 (78%) were found to be eligible 
for ART at baseline, while 719 (22%) were not. Four of the latter 
were transferred out. Of the remaining 715 individuals enrolled 
in pre-ART care, 64% were females, and the mean (standard devi-
ation) age was 33 (±11.2) years. At one year after registration, 425 
(59%) were retained in pre-ART care and 290 (41%) had been lost 
to follow-up (Figure 2). Of those retained in care, 83 (20%) be-
came eligible and were started on ART at their first follow-up visit 
after registration.
The demographic and clinical characteristics of patients lost to 
follow-up and those retained in care are compared in Table 1. The 
two groups differed significantly with respect to age, education 
and residence. Patients in WHO Clinical Stage III or IV repre-
sented those co-infected with pulmonary tuberculosis (TB).
Table 2 shows the results of bivariate and multivariate analysis 
examining factors associated with loss to follow-up. On bivariate 
analysis, age, education and WHO staging were found to be statis-
tically significant. All variables except occupation and CD4 count 
were included in the multivariate analysis to rule out the possibil-
ity of negative confounding due to any variable. Occupation 
(with subcategory ‘housewife’) and CD4 count were not included 
in the final model, due to collinearity with the variables sex (with 
the subcategory female) and WHO clinical staging, respectively. 
Significant factors associated with greater risk of loss to follow-up 
on multivariate analysis included age group 45 years, low edu-
cational level, being unmarried, rural residence and WHO Stage 
III or IV (Table 2). A significant linear trend in loss to follow-up 
was associated with the level of education.
FIGURE 2 Retention of HIV-infected persons in 
pre-ART care in Tumkur district ART centre, Karna-
taka, India, January 2010–June 2012. * Among the 
425 (59%) who were retained in care, 83 (20%) 
were initiated on ART as they were found to be eli-
gible. HIV = human immunodeficiency virus; ART = 
antiretroviral treatment; WHO = World Health 
Organization.
TABLE 1 Demographic and clinical characteristics of patients lost to follow-up 
and retained in pre-ART care in Tumkur district, Karnataka, India, January 2010–
June 2012
Variable
LFU 
n (%)
Retained in care
n (%) P value
Sex
 Female 175 (60) 282 (66) 0.23
 Male 112 (39) 138 (33)
 Transsexual/-gender 3 (1) 5 (1)
Age group, years
 15–34 140 (48) 278 (65) 0.001
 35–44 83 (29) 94 (22)
 45 67 (23) 53 (13)
Marital status
 Married 232 (80) 360 (85) 0.10
 Single/separated/widowed 58 (20) 65 (15)
Education
 Illiterate 136 (47) 137 (32) 0.001
 1–7 years of schooling 86 (30) 111 (26)
 >7 years of schooling 68 (23) 177 (42)
Occupation
 Housewife 105 (36) 179 (42) 0.12
 Daily wage worker 139 (48) 174 (41)
 Agriculturist 32 (11) 40 (9)
 Semi-skilled/skilled worker 14 (5) 32 (8)
Residence
 Urban 57 (20) 110 (26) 0.05
 Rural 233 (80) 315 (74)
WHO Clinical Stage
 I   32 (11) 49 (12) 0.16
 II 236 (81) 360 (84)
 III 19 (7) 13 (3)
 IV 3 (1) 3 (1)
CD4 group, cells/mm3
 350–499 138 (48) 219 (51) 0.30
 500 152 (52) 206 (49)
ART = antiretroviral treatment; LFU = lost to follow-up; WHO = World Health Organization.
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DISCUSSION
This is the first study from India to assess pre-ART retention at a 
district-level ART centre in Karnataka state, showing that only 
about six in 10 individuals remained in care 1 year after registra-
tion. These findings are not encouraging, although marginally bet-
ter than in a similar district-level study from Malawi, which showed 
a low retention of 4% at 6 months,10 a study from South Africa 
with a pre-ART retention of 43%,11 and findings of a systematic re-
view from sub-Saharan Africa, where only a third of patients were 
retained.7 Few recent studies from sub-Saharan Africa have reported 
similar12 or better13 retention rates after accounting for the real rea-
sons for loss to follow-up. We feel nevertheless that a loss to fol-
low-up rate of 41% is high, and more effort is warranted to improve 
the situation. In India an estimated 500 000 individuals are in pre-
ART care, and if the proportion of loss to follow-up seen in our 
study is reflective of the general situation, it would crudely extrapo-
late to 205 000 individuals countrywide. Loss to follow-up serves as 
a proxy for challenges in pre-ART management, and overcoming 
these would directly benefit patients and the community at large.
The strengths of the study are that the findings come from a 
routine setting and are likely to reflect the situation on the 
ground, and the cohort included all patients registered in pre-ART 
care. Further, we believe the data are robust, as cross-verification 
had been performed between treatment cards and registers, with 
data being double entered and validated. We also adhered to 
Strengthening the Reporting of Observational studies in Epidemi-
ology (STROBE) guidelines,14 including ethics, in reporting this 
research.15
How can we improve current pre-ART retention rates in 
India?
Indian guidelines for cotrimoxazole prophylaxis therapy (CPT) 
for the prevention of opportunistic infections is restricted to 
those with WHO Clinical Stage III/IV and/or those with a CD4 
count 250 cells/mm³. Isoniazid preventive therapy is also not 
offered, due to concerns about the feasibility of its implementa-
tion among national policy makers in India, although a pilot 
study is ongoing which is expected to inform future scale-up deci-
sions. There is thus no real incentive or ‘offer’ to patients for re-
turn visits except for a CD4 count test. Current WHO guidelines 
recommend CPT for all individuals with CD4 count 500 cells/
mm³ in areas where bacterial infections and malaria are com-
mon.16 The NACP could thus consider increasing the threshold 
TABLE 2 Factors associated with loss to follow-up during pre-ART care in Tumkur district, 
Karnataka, India, January 2010–June 2012
Variable Total
LFU
n (%)
RR
(95%CI)
Adjusted RR
(95%CI)
Total 715 290 (41) — —
Sex
 Female 457 175 (38) 1 1
 Male 250 112 (45) 1.2 (1.0–1.4) 1.1 (1.0–1.3)
 Transsexual/-gender 8 3 (37) 1.0 (0.4–2.4) 1.0 (0.5–2.3)
Age group, years
 15–34 418 140 (33) 1
 35–44 177 83 (47) 1.4 (1.1–1.7) 1.2 (1.0–1.5)*
 45 120 67 (56) 1.7 (1.4–2.1)* 1.4 (1.2–1.8)*
Marital status
 Married 592 232 (39) 1 1
 Single/separated/widowed 123 58 (47) 1.2 (1.0–1.5) 1.3 (1.1–1.6)*
Education†
 Illiterate 273 136 (50) 1
 1–7 years of schooling 197 86 (44) 0.9 (0.7–1.1) 0.9 (0.8–1.1)
 7 years of schooling 245 68 (28) 0.6 (0.4–0.7)* 0.6 (0.5–0.8)*
Occupation
 Housewife 284 105 (37) 1
 Daily wage worker 313 139 (44) 1.2 (1.0–1.5)
 Agriculturist 72 32 (44) 1.2 (0.9–1.6)
 Semi-skilled/skilled worker 46 14 (30) 0.8 (0.5–1.3)
Residence
 Urban 167 57 (34) 1 1
 Rural 548 233 (42) 1.2 (1.0–1.6) 1.3 (1.1–1.6)*
WHO Clinical Stage
 I and II 677 268 (40) 1 1
 III and IV 38 22 (58) 1.5 (1.1–1.9)* 1.3 (1.1–1.6)*
CD4 group, cells/mm3
 350–499 357 138 (39) 1
 500 358 152 (42) 1.1 (0.9–1.3)
* Statistically significant, P  0.05.
† χ2 for linear trend = 26.2, P  0.0001.
ART = antiretroviral treatment; LFU = lost to follow-up; RR = relative risk; CI = confidence interval; WHO = World Health 
Organization.
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for CPT initiation. The 2013 WHO ART guidelines also recom-
mend initiating ART for all individuals with a CD4 count 500 
cells/mm³.3 If these two recommendations had been followed, a 
considerable proportion of individuals who were in pre-ART care 
in this study and were subsequently lost to follow-up with a CD4 
count 350–499 cells/mm³ (38%) would have started CPT and/or 
ART and might have been retained. About one fifth of the pa-
tients retained in care became eligible for ART even in accordance 
with current guidelines, and were initiated on ART.
Three unique registration numbers are currently being given to 
patients at the three levels of the patient care pathway: at the HIV 
testing site, at the pre-ART stage and while on ART. As India is 
moving towards an electronic online database system for HIV-in-
fected persons, there is an excellent opportunity to move towards 
a unique patient identification number at all levels of the care 
pathway. The NACP could introduce monthly reporting on pre-
ART, as is currently done for those on ART. This will enhance co-
hort monitoring and tracing of patients lost to follow-up.17
Individuals aged 45 years and from rural areas have a signifi-
cantly higher chance of being lost to follow-up. This may be due 
to socio-economic hardship, including the inability to pay for 
transport costs for a return visit. Karnataka state has already initi-
ated a scheme that provides travel allowance to patients, but this 
is restricted to those on ART. It would now seem logical to also 
extend this laudable initiative to those in pre-ART care. There 
have also been recent initiatives to link HIV-infected people to ex-
isting social welfare schemes, although the impact of these on pa-
tient retention is yet to be evaluated. In addition, being unmar-
ried was associated with a higher risk of loss to follow-up, 
suggesting the importance of family support in ensuring reten-
tion in care. Patients in WHO Stage III or IV had a higher risk of 
loss to follow-up and could represent unaccounted for deaths. 
These included patients co-infected with pulmonary TB but with 
a CD4 count of 350 cells/mm3 and thus ineligible for ART at the 
time of the study. The guidelines to start ART in all HIV-TB pa-
tients, irrespective of CD4 count, came into effect in March 2012. 
While most of these factors have already been identified by stud-
ies elsewhere, this is the first time there has been published infor-
mation from India, and such local evidence is important for deci-
sion making.
There have been efforts to standardise the definition of loss to 
follow-up among patients started on ART, thus minimising mis-
classifications.18 Similar efforts are needed for patients in pre-ART 
care to ensure uniformity in reporting across the globe.
Finally, reinforcing outreach tracing, improved counselling 
and peer support mechanisms at community level may enhance 
retention, as has been shown in sub-Saharan Africa.19, 20
There are some study limitations. We used a 1-year cut-off pe-
riod to declare a patient as lost to follow-up, but such patients 
may attend for follow-up after this time. Those retained may also 
be lost after the cut-off used in this study. This may influence the 
real retention rates in the long term. We assessed retention from 
the time of registration, but losses are also known to occur before 
this stage, between HIV testing and registration, and this was not 
captured in our study. The overall losses in pre-ART care may thus 
be higher.7,8 We also do not know the exact reasons why patients 
were lost to follow-up. Anecdotal evidence during informal inter-
actions with outreach workers and patients suggested three main 
reasons: being clinically asymptomatic, migration or wrong ad-
dress provided at the time of registration and death. While other 
studies have shown that ‘unaccounted transfers’, reflecting pa-
tients on care elsewhere (including those on care in the private 
health sector), have accounted for loss to follow-up, we feel that 
this represents a negligible proportion in our setting.13,21 Further 
qualitative research and a sampling-based approach to interview a 
random sample of patients lost to follow-up are required to con-
firm these, ascertain other reasons and guide future interven-
tions.22,23 Finally, this study focused on one of the 55 nodal ART 
centres that currently exist in Karnataka state, thus limiting the 
generalisability of the findings. The indicator for pre-ART loss to 
follow-up is now part of routine reporting from all the ART cen-
tres, and this is expected to inform the state-wide situation. All of 
these aspects merit specific operational research.
CONCLUSION
Pre-ART retention at an ART centre in Karnataka State, India, was 
not encouraging, and further efforts are warranted to improve the 
situation for the benefit of patients and the community at large. 
Routine cohort analysis in the national programme should in-
clude patients in pre-ART care in addition to those on ART, to en-
able improved review, monitoring and supervision. Further quali-
tative research to ascertain reasons for loss to follow-up is required 
to design future interventions.
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Contexte  :  Centre de traitement antirétroviral (ART) du district de 
Tumkur dans l’état de Karnataka, Inde. Il n’y a pas de document 
publié sur les perdus de vue avant le traitement ART en Inde.
Objectif  :  Evaluer la proportion de perdus de vue (définis comme 
l’absence de visite au centre d’ART dans l’année suivant 
l’enregistrement) et les variables sociodémographiques et 
immunologiques qui y sont associées.
Schéma  :  Etude rétrospective de cohorte impliquant une revue des 
dossiers médicaux des patients adultes infectés par le VIH (âge 15 
ans) enregistrés en soins pré-ART entre janvier 2010 et juin 2012.
Résultats  :  Sur 3238 patients enregistrés, 2519 (78%) étaient 
éligibles pour le traitement ART tandis que 719 (22%) ne l’étaient 
pas. Quatre de ces derniers ont été transférés. Parmi les 715 individus 
enrôlés en soin pré-ART, 290 (41%) ont été perdus de vue. Les 
facteurs associés avec le fait d’être perdus de vue en analyse 
multivariée incluaient la tranche d’âge 45 ans, un niveau 
d’instruction faible, le célibat, le stade 3 ou 4 de l’OMS et la résidence 
en milieu rural.
Conclusion  :  Près de quatre individus sur 10 en soins pre-ART ont été 
perdus de vue dans l’année suivant leur enregistrement. Ceci requiert 
une attention urgente. L’analyse de cohorte en routine du 
programme national devrait inclure les patients en soins pré-ART afin 
d’améliorer la revue des cas, leur suivi et leur supervision. Une 
recherche qualitative ultérieure afin de cerner les raisons des pertes 
de vue est nécessaire pour concevoir les interventions futures.  
Marco de referencia: El centro de tratamiento antirretrovírico (ART) 
en el distrito de Tumkur del estado de Karnataka en la India. Hasta el 
momento no existen publicaciones sobre la pérdida de vista de los 
pacientes seropositivos durante el seguimiento antes de comenzar el 
ART en la India.
Objetivo: Se buscó definir la proporción de pacientes perdidos de 
vista durante el seguimiento (definidos como los pacientes que no 
habían acudido al centro de ART hasta un año después de haberse 
registrado) y evaluar las variables socioeconómicas e inmunitarias que 
se asociaban con esta situación.
Método: Se llevó a cabo un estudio retrospectivo de cohortes a 
partir del examen de las historias clínicas de los adultos (15 años de 
edad) infectados por el virus de la inmunodeficiencia humana (VIH), 
que se inscribieron a la atención clínica previa al ART de enero del 
2010 a junio del 2012.
Resultados: De los 3238 pacientes registrados, 2519 cumplían con 
los requisitos para iniciar el ART (78%) y 719 de ellos no eran aptos 
(22%); cuatro pacientes de este último grupo se remitieron a otro 
centro. De las 715 personas restantes, inscritas en la atención previa 
al ART, 290 se perdieron de vista durante el seguimiento (41%). El 
análisis multifactorial puso en evidencia que los factores asociados 
con la pérdida de vista de los pacientes fueron el grupo de edad de 
45 años, una baja escolaridad, el hecho de ser solteros, el estado 3 
o 4 de la enfermedad según la clasificación de la Organización 
Mundial de la Salud y la residencia en zona rural.
Conclusión: Cerca de cuatro de cada diez pacientes inscritos en la 
atención clínica previa al ART se perdieron de vista durante el 
seguimiento en el primer año después de haberse registrado. Esta 
situación exige una atención urgente. Es importante que los análisis 
sistemáticos de cohortes del programa nacional incluyan a las 
personas infectadas que reciben atención antes de comenzar el ART, 
a fin de mejorar la evaluación, el seguimiento y la supervisión de los 
pacientes. Es preciso fomentar la realización de nuevas investigaciones 
cualitativas que determinen las razones de la pérdida de vista durante 
el seguimiento y contribuyan a la planificación de las intervenciones 
futuras.
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